H-Index
34
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
Medical Science Monitor Basic Research

AmJCaseRep
MedSciTechnol

eISSN: 2329-0358

Severe Cytomegalovirus Infection in a Second Kidney Transplant Recipient Treated with Ganciclovir, Leflunomide, and Immunoglobulins, with Complications including Seizures, Acute HCV Infection, Drug-Induced Pancytopenia, Diabetes, Cholangitis, and Multi-Organ Failure with Fatal Outcome: A Case Report

Dorota Miszewska-Szyszkowska, Natalia Mikołajczyk, Ewa Komuda-Leszek, Renata Wieczorek-Godlewska, Robert Świder, Dominika Dęborska-Materkowska, Jacek Szmidt, Magdalena Durlik

Department of Transplantation Medicine and Nephrology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland

Ann Transplant 2015; 20:169-174

DOI: 10.12659/AOT.892076

Available online: 2015-03-27

Published: 2015-03-27


#892076

Background: Cytomegaly remains one of the most common infectious complications in organ transplant recipients, and the course of the infection may have a negative effect on survival of the transplant and recipient.
Case Report: We describe the case of a 32-year-old female patient who received a second kidney transplant from a cadaveric donor in July 2012, treated successfully with ganciclovir for primary CMV infection in August 2012 and then re-treated from November due to re-infection. The viral load at the start of re-treatment was 6 million copies. In view of ganciclovir treatment failure, Sando immunoglobulins were administered. Subsequently, when CMV viral load increased to 18 million copies, a decision was made to use combination treatment with leflunomide and ganciclovir. Immunosuppressive treatment was also modified by administering everolimus in view of its potential antiviral activity. Seizures, pancytopenia, diabetes, diarrhoea, and (probably) drug-induced liver damage and cholangitis were observed in the course of treatment. At 3 months of hospitalization, the patient was discharged home with viral load of 8000 copies. As treatment continuation, she received valganciclovir at the full therapeutic dose in view of very good kidney function (creatinine 0.7 mg/dl). The patient was re-hospitalized after 10 days due to fever and cough. Due to abnormal liver function test results and negative serum markers of viral hepatitis, HCV RNA was tested, with a positive result (above 10^8 copies). Subsequently, decline in clinical status, overhydration, increasing creatinine levels, hepatic failure signs, and renewed CMV DNA increase to 520 000 copies were observed. Despite intensive treatment, the patient died of multi-organ failure.
Conclusions: The case described illustrates the difficulties in the treatment of CMV infection and its possible dramatic complications.

Keywords: Cytomegalovirus, Ganciclovir, Immunoglobulins



Back